Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary) ; Dasatinib; Imatinib; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 19 Apr 2019 Planned End Date changed from 31 Jul 2020 to 31 Jul 2021.
- 19 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2018 Results (n=8) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology